diabetes

Sanofi CEO Paul Hudson announced on Tuesday the creation of a nonprofit unit, Sanofi Global Health, which will provide 40 lower-income countries with access to 30 of the company’s “most essential medicines,” including cardiovascular, diabetes, tuberculosis, malaria and cancer treatments.

An accompanying press release said Sanofi Global Health will be the cornerstone of the Paris-based company’s corporate social responsibility strategy for “access to medicines, support for vulnerable…

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Takeda continued its ongoing business restructuring on Friday, announcing that it will transfer four of its Type 2 diabetes medications for the Japanese market to Teijin Pharma for $1.2 billion. Takeda will continue to manufacture and supply the drugs but will hand off marketing authorization to the Tokyo-based drugmaker, the press release said.

The deal is the latest noncore asset sell-off for the Japanese company as it seeks to refocus its business on five key areas (gastroenterology…

Four pharma companies recently announced moves to increase access to medicines.

Ahead of World Neglected Tropical Disease (NTD) Day (January 30), Novartis renewed its leprosy multidrug therapy donation program with WHO—extending the commitment by five years to the end of 2025. The agreement also includes the donation of fascioliasis drug triclabendazole.

On the same day, Germany’s Merck KGaA announced that it will provide an additional 8 million tablets of praziquantel per year…

The UN’s Medicines Patent Pool (MPP) and the International Diabetes Federation announced this week that they have signed a memorandum of understanding to improve access to affordable diabetes medication in low- and middle-income countries (LMICs). The two organizations will work together to identify patented medicines that could benefit from “MPP’s proven model of public health-oriented voluntary licensing” and to study diabetes drug-related “needs and barriers to access” in LMICs, a press…

WHO announced receipt this week of its first donation of medicine for a noncommunicable disease, with Novo Nordisk providing $1.3 million worth of insulin and glucagon for people with diabetes, for use in 50 low- and middle-income countries. The press release did not specify if it was a one-time or reoccurring donation from the Danish company, which shares control of most of the global insulin market with Eli Lilly and Sanofi.

Novo Nordisk also announced today its new social…

Evaluate’s publishing arm Vantage issued its annual markets forecast last month predicting “a rocky year” for pharma companies in 2020 with “areas of significant growth contrasting with investor uncertainty.”

The analyst group said cancer, vaccines and diabetes will continue strong sales in 2020. However, industry will need to “deliver on its innovation promises” if it hopes to rise above “wider economic and financial concerns”—especially over U.S. drug pricing.

Vantage said…

WHO announced last week that it will begin a pilot program for insulin prequalification, which it hopes will lower prices and increase access by promoting the flow of quality-assured generic products to the international market. Eli Lilly, Novo Nordisk and Sanofi control most of the global market for the diabetes treatment, “setting prices that are prohibitive for many people and countries,” the press release said.

J&J announced last week that Everett, Washington–based industrial-equipment firm Fortive has offered $2.7 billion for its medical sterilization unit. If accepted, the transaction will close in early 2019.

Yesterday, J&J updated investors that it has accepted Platinum Equity’s $2.1 billion offer from March for its LifeScan blood glucose monitoring business.

Mentions:

Johnson & Johnson (J&J) announced last week that Platinum Equity will acquire its LifeScan blood glucose monitoring business for $2.1 billion. J&J said it expects the transaction to close by the end of the year.

Mentions: